News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

https://www.prnewswire.com/news-releases/immunitybio-and-ncartes-enter-collaboration-agreement-on-clinical-trial-data-fulfillment-302312171.html

https://wsw.com/webcast/jeff315/ibrx/1857828?mobile=True

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-anktivas-post-approval-enrollment-100th?field_nir_news_date_value[min]=

Q3 2024: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-third-quarter-2024-financial-results?field_nir_news_date_value[min]=

https://youtu.be/sOOvztLtZAQ

Bisschen Klatschpresse: https://www.boersennews.de/nachrichten/artikel/%22So-viel-Potenzial%22:-Diese-Aktie-kann-um-650-Prozent-steigen,-sagt-ein-Analyst/4594482/?utm_source=BoersennewsShare&utm_medium=App&utm_campaign=News

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma https://ir.immunitybio.com/news-releases/news-release-details/first-patients-dosed-phase-1-clinical-study-immunitybios-car-nk?field_nir_news_date_value[min]=

https://www.investing.com/news/company-news/ef-hutton-sets-stock-target-with-buy-rating-for-immunitybio-cites-cancer-therapy-93CH-3677443

ImmunityBio to Participate in the Jefferies London Healthcare Conference https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-participate-jefferies-london-healthcare-conference-0?field_nir_news_date_value[min]=

Globaler Markt für Bacillus Calmette-Guérin (BCG)-Impfstoffe – Branchentrends und Prognose bis 2028 https://www.databridgemarketresearch.com/de/reports/global-bacillus-calmette-guerin-bcg-vaccine-market

https://seekingalpha.com/article/4725428-immunitybio-moving-the-needle

https://youtu.be/GjCAGq6FCxA